Clinical Trials

Multiple clinical trials sponsored by Novartis Pharmaceuticals have evaluated penciclovir-related therapeutic regimens for viral infections, specifically herpes labialis and herpes simplex. These completed late-stage studies, encompassing Phase II and Phase III trials, evaluated safety, dosing parameters, tolerability, and pharmacokinetic profiles in adolescent and adult populations. Overall, these clinical investigations validated the therapeutic safety, tolerability, and pharmacokinetic characteristics of penciclovir for treating recurrent cold sores.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00878072 Completed
Herpes Labialis
Novartis Pharmaceuticals|Novartis
 2009-03-25 Phase 2|Phase 3
NCT00098059 Completed
Herpes Simplex
Novartis Pharmaceuticals|Novartis
 2005-02 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Penciclovir product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Penciclovir is phosphorylated by viral thymidine kinase to its monophosphate form and subsequently converted by cellular kinases into penciclovir triphosphate, which competitively inhibits viral DNA polymerase and halts viral DNA chain elongation. By suppressing viral genomic replication within infected host cells, penciclovir reduces viral shedding and accelerates lesion healing in patients suffering from herpes simplex and herpes labialis infections.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.